Search results
It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put...
Simply Wall St. via Yahoo Finance· 2 days agoWhile this analysis focuses on total compensation, it's worth acknowledging that the salary portion...
COMMENTARY: Price controls kill more than innovation
Las Vegas Review-Journal· 13 hours agoArtificially lower costs do not mean greater access. Sanders’ pharmaceutical price controls will not only reduce future drug development but also cripple...
Celebrity doctors promoted Covid vaccine without declaring payments
The Telegraph via Yahoo News· 1 day agoThe pharmaceutical watchdog has been urged to investigate after a string of celebrity doctors took...
Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceutica
Guru Focus· 4 days agoOn June 5, 2024, Brian Goff, Chief Executive Officer of Agios Pharmaceuticals Inc (AGIO, Financial),...
BMO maintains target on Eli Lilly shares amid growth outlook By Investing.com
Investing.com· 6 days agoThe endorsement follows a recent oncology analyst event hosted by the pharmaceutical company, which...
NJ health care, pharmaceutical companies cutting jobs as tech disrupts industry
The Bergen Record via Yahoo News· 2 days agoSome of the largest pharmaceutical and health care companies in New Jersey are cutting their head...
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued
Simply Wall St. via Yahoo Finance· 6 days agoDebt is well covered by earnings and cashflows. Dividends are covered by earnings and cash flows....
Insider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Ve
Guru Focus· 6 days agoAccording to the SEC Filing, the transaction was executed at a stock price of $460, totaling $1,495,000. Following this transaction, the insider now owns 47,137 shares of Vertex Pharmaceuticals ...
A Quick Glance At Apellis Pharmaceuticals Inc (NASDAQ: APLS) Stock: It Is up 52.22% From Its 52-Week...
Marketing Sentinel· 3 days agoApellis Pharmaceuticals Inc (APLS) shares have gone down -35.02% during the last six months, with a year-to-date growth rate more than the industry average ...
Cyclacel Pharmaceuticals maintains $11 target, Buy rating By Investing.com
Investing.com· 6 days agoOn Monday, Roth/MKM maintained its Buy rating and $11.00 price target for Cyclacel Pharmaceuticals...